Immedica acquires the rights for additional Ophthalmology products for European countries


Immedica Pharma AB (Immedica) has acquired rights from Novartis to five ophthalmology products involving indications for the treatment of glaucoma and inflammatory conditions of the eye, in certain European countries. The deal encompasses commercial and distribution rights and intellectual property for the five products in the territories.

All five products are part of standard pharmaceutical treatments in their respective indications and territories, and the products constitute valuable and reliable treatment options for numerous patients in this specialty care field.

“We are very happy to conduct another transaction with Novartis, and being able to offer these important products to patients in these countries also in the future.” says Anders Edvell, CEO of Immedica.

During an initial transition period Immedica will collaborate with Novartis for the commercial operations of the products. Immedica will after the transition period assume direct distribution and sales operations in its territory.

“These five ophthalmology products will be important in the continued growth of Immedica in Europe, and also for our continued commitment towards specialty care patients and care-givers, primarily in Europe,” concludes Anders Edvell.

About Immedica Pharma AB

Immedica is a fast-growing private niche specialty pharma group, with the headquarter based in Stockholm, Sweden, and the company has direct commercial coverage across Europe and the Middle East.

Immedica provides significant know-how and experience from commercialization of niche/specialty care products across Europe and the Middle East, and the company’s management team has an outstanding track record of transactions and operating niche pharma products internationally. Immedica has capabilities to provide optimal access of specialty care medicines to patients with significant medical needs, including key areas such as regulatory affairs, pharmacovigilance, medical affairs, pricing & reimbursement, quality and product distribution.


Anders Edvell – CEO
Phone +46 705 44 61 26